SAGE
$36.00
Sage Therapeutic Com
$.77
2.19%
SAGE
Earnings Whisper ®
N/A
2nd Quarter June 2020
Consensus:  ($2.67)
Revenue:  $1.20 Mil
Thursday
Aug 6
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when SAGE reports earnings?
Beat
Meet
Miss

Where is SAGE's stock price going from here?
Up
Flat
Down
Stock chart of SAGE
Analysts
Summary of analysts' recommendations for SAGE
Score
Grade
Pivots
Resistance
$38.39
$37.43
$36.71

$35.75

Support
$35.03
$34.07
$33.35
Tweet
Growth
Description
SAGE Therapeutics Inc. is a biopharmaceutical company developing and commercializing medicines to treat life-threatening central nervous system (CNS) disorders. The Company provides treatments for schizophrenia, major depressive disorder, pain, and traumatic brain injury conditions. Its initial product candidates include SAGE-547, SAGE-689 and SAGE-217. SAGE Therapeutics, Inc. is based in Cambridge, Massachusetts.
Peers
Regeneron PharmaceuticalsVertex PharmaceuticalsBioMarin PharmaceuticalJohnson & JohnsonInterCeptZoetisMylanBristol-Myers SquibbUltragenyx PharmaceuticalEndo International plc